AI assistant
Acticor Biotech — Capital/Financing Update 2022
Jan 13, 2022
1070_rns_2022-01-13_e5a6e682-0f6c-4a20-8c95-eb2cca1555aa.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT WITH THE BROKERAGE FIRM KEPLER CHEUVREUX
COMMUNIQUÉ DE PRESSE
Paris, France, January 13, 2022 at 06:00 pm CET - ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.
Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:
- 62,031 shares
- € 191,956.52
- Number of executions on buy side on semester: 264
- Number of executions on sell side on semester: 42
- Traded volume on buy side on semester: 67,876 shares for € 445,195.95
- Traded volume on sell side on semester: 5,845 shares for € 37,412.21
As a reminder the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 600,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), that is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes.
Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab) directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the risk of bleeding, particularly intracerebral hemorrhage.
Acticor Biotech is supported by a panel of European and International Investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris, since November 2021 (ISIN: FR0014005OJ5 – ALACT).
For further information, please go to www.acticor-biotech.com
Contacts
ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder [email protected] T. : +33 (0)6 76 23 38 13
NewCap Mathilde BOHIN / Olivier BRICAUD Investor Relations [email protected] T. : +33 (0)1 44 71 94 95
Sophie BINAY, PhD General Manager and CSO [email protected] T. : +33 (0)6 76 23 38 13
Appendix
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR | Number of executions |
Number of shares |
Traded volume in EUR | |
| Total | 264 | 67 876 | 445 195.95 | 42 | 5 845 | 37 412.21 |
| 01/11/2021 | 37 | 26 763 | 189 214.41 | - | - | - |
| 02/11/2021 | 10 | 4 977 | 34 639.92 | - | - | - |
| 03/11/2021 | 22 | 4 799 | 33 113.10 | - | - | - |
| 04/11/2021 | 14 | 3 224 | 21 697.52 | - | - | - |
| 05/11/2021 | 3 | 450 | 3 006.00 | 5 | 1 500 | 10 950.00 |
| 08/11/2021 | - | - | - | 8 | 1 500 | 10 470.00 |
| 09/11/2021 | 5 | 1 000 | 6 850.00 | 4 | 23 | 161.00 |
| 10/11/2021 | 7 | 1 000 | 6 870.00 | - | - | - |
| 11/11/2021 | 4 | 500 | 3 415.00 | - | - | - |
| 12/11/2021 | 3 | 358 | 2 445.14 | 1 | 1 | 6.95 |
| 15/11/2021 | 1 | 142 | 969.86 | - | - | - |
| 16/11/2021 | 10 | 3 509 | 23 510.30 | - | - | - |
| 17/11/2021 | 4 | 896 | 5 850.88 | - | - | - |
| 18/11/2021 | 10 | 1 000 | 6 640.00 | 1 | 2 | 13.40 |
| 19/11/2021 | 15 | 2 650 | 16 748.00 | 1 | 1 | 6.60 |
| 22/11/2021 | - | - | - | 3 | 801 | 5 286.60 |
| 23/11/2021 | 1 | 400 | 2 600.00 | 1 | 1 | 6.60 |
| 24/11/2021 | 4 | 400 | 2 592.00 | 1 | 9 | 59.40 |
| 26/11/2021 | 6 | 1 201 | 7 710.42 | 2 | 161 | 1 046.50 |
| 29/11/2021 | 6 | 950 | 5 918.50 | - | - | - |
| 30/11/2021 | 10 | 1 100 | 6 677.00 | - | - | - |
| 01/12/2021 | 1 | 1 | 5.90 | - | - | - |
| 02/12/2021 | 9 | 1 270 | 7 442.20 | 1 | 1 | 5.98 |
| 03/12/2021 | 2 | 2 | 11.40 | - | - | - |
| 06/12/2021 | 8 | 328 | 1 869.60 | - | - | - |
| 07/12/2021 | 13 | 1 060 | 5 808.80 | - | - | - |
| 08/12/2021 | 7 | 1 325 | 7 155.00 | - | - | - |
| 09/12/2021 | - | - | - | 3 | 401 | 2 245.60 |
| 10/12/2021 | 2 | 124 | 669.60 | 2 | 501 | 2 755.50 |
| 14/12/2021 | 7 | 1 392 | 7 516.80 | - | - | - |
| 15/12/2021 | 4 | 400 | 2 120.00 | - | - | - |
| 16/12/2021 | 7 | 801 | 4 213.26 | 1 | 1 | 5.30 |
| 17/12/2021 | 8 | 1 445 | 7 239.45 | - | - | - |
| 20/12/2021 | 3 | 800 | 3 944.00 | - | - | - |
| 21/12/2021 | 2 | 555 | 2 680.65 | - | - | - |
| 22/12/2021 | 5 | 500 | 2 365.00 | - | - | - |
| 23/12/2021 | 7 | 1 000 | 4 570.00 | - | - | - |
| 24/12/2021 | - | - | - | 2 | 400 | 1 880.00 |
| 29/12/2021 | 5 | 1 000 | 4 590.00 | 1 | 200 | 932.00 |
| 30/12/2021 | 1 | 500 | 2 280.00 | 2 | 238 | 1 097.18 |
| 31/12/2021 | 1 | 54 | 246.24 | 3 | 104 | 483.60 |